Abstract
B cells are classically considered for their unique capacity to produce antibodies. Besides this, B cells can also present antigen, costimulate T cells, and secrete cytokines. Recent studies have demonstrated that activated B cells could regulate immunity by the secretion of anti-inflammatory cytokines. Because of their capacity to inhibit immune responses, B cells became of interest as a potential vehicle for the treatment of autoimmune disorders via cell-based therapy. Different approaches have been developed to empower B cells with regulatory properties. An attractive strategy involves their genetic engineering to enforce their expression of suppressive genes. This can be achieved using retroviral vectors. However, most retroviral vectors require prior activation of the B cells for transduction, and the administration of activated B cells may lead to unpredictable outcomes in recipients, including to an enhancement of immune responses. In contrast, resting B cells are poorly immunogenic and therefore safer for the suppression of undesired immune responses in adoptive cell therapy. In this chapter, we describe an approach to generate genetically modified resting B cells with lentiviral vectors using a protocol that is rapid, simple, and neither requires nor induces activation of B cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Anderton SM, Fillatreau S (2008) Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 4(12):657–666
Duddy M, Niino M, Adatia F et al (2007) Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099
Fillatreau S, Sweenie CH, McGeachy MJ et al (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944–950
Scott DW (2010) Gene therapy for immunological tolerance: using “transgenic” B cells to treat inhibitor formation. Haemophilia 16(102):89–94
Schultze JL, Michalak S, Seamon MJ et al (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757–2765
Ito O, Harada M, Takenoyama M et al (1998) Vaccination with activated B cells pulsed with tumor-lysates can induce tumor specific CD4 + T cells in vivo. Immunobiology 199(1):133–147
Eynon EE, Parker DC (1992) Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175:131–138
Fuchs EJ, Matzinger P (1992) B cells turn off virgin but not memory T cells. Science 258:1156–1159
Calderón-Gómez E, Lampropoulou V, Shen P et al (2011) Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalitis. Eur J Immunol 41:1696–1708
Naldini L, Blömer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267
Zennou V, Petit C, Guetard D et al (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185
Rubinson DA, Dillon CP, Kwiatkowski AV et al (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401–406
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Calderón-Gómez, E., Fillatreau, S. (2014). Utilization of a Lentiviral System for the Generation of B Cells with Regulatory Properties. In: Vitale, G., Mion, F. (eds) Regulatory B Cells. Methods in Molecular Biology, vol 1190. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1161-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1161-5_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1160-8
Online ISBN: 978-1-4939-1161-5
eBook Packages: Springer Protocols